Advanced Oncotherapy Four components integrated

Hardman & Co Report Report DownloadsAdvanced Oncotherapy (LON:AVO)  goal is to deliver an affordable and novel proton therapy system (PT), based on
state-of-the-art technology developed originally at the world-renowned CERN.
Achievement of major technical milestones has boosted confidence greatly, and the
group remains on track with its strategy. AVO has successfully integrated the four types
of structures that constitute the LIGHT accelerator and has overcome technical
challenges. The proton beam has been recorded at an energy of 52MeV, sufficient to
treat superficial tumours. With the distribution agreement in place for SE Asia,
partnerships with both RaySearch and the STFC, and strengthening of its financing
structure, AVO is now on a much firmer footing.

Strategy: AVO is developing a compact and modular PT system at an affordable
price for the payor, financially attractive to the operator, and generating superior
patient outcomes. AVO benefits from the technology know-how developed by
ADAM, Geneva, and relies on a base of world-class suppliers.

► Major milestone achieved: The biggest technical challenge for the proton
accelerator has now been overcome. Integration of all the four components at
CERN’s testing facility in Geneva is, in our opinion, a major milestone that
significantly de-risks the whole project. AVO now has an accelerator that has
been powered-up, demonstrated its ability to perform as predicted, and
accelerated a proton beam to an energy of 52MeV.

Interims: Investment in LIGHT during 2018 has been broadly in line with our
forecasts. Moreover, to date in fiscal 2018, AVO has raised ca.£40m, which has
left the balance sheet debt-free and with net cash of £3.3m, boosted
subsequently by a Placing (£6.4m gross) and a tax credit of £2.9m, providing
flexibility in future funding discussions.

Risks: With funding secured so far in 2018, AVO’s visibility and its ability to
maintain the fast pace of its development plan have improved. Execution risk
remains, but the more complex technical challenges have now been overcome,
and integration of the remaining CCL units is a technically easy step towards
getting a fully functional accelerator.

Investment summary: Demand for PT is increasing worldwide, and the need for a
small, flexible, affordable and close-to-patient system is desirable. Advanced Oncotherapy has
attracted strong partners, and discussions with potential customers are
advancing. Progress at the flagship Harley Street site has been substantial and
installation of the first LIGHT system is planned to start in mid-2019. The latest
technical update has brought further assurance and boosted confidence.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Advanced Oncotherapy: Understanding the significance of 230MeV

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of the first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: Major milestone achieved

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of its first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: LIGHT – regulatory update

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. The company is in the process of completing the complex

    Hardman & Co

    Advanced Oncotherapy: On the home straight

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Funded to completion

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Leveraging the modularity of LIGHT

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy funded through to clinical events

    AVO’s goal is to deliver an affordable and novel proton therapy (PT) system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, the project has been significantly de-risked

    Hardman & Co

    Advanced Oncotherapy Rapidly changing to commercial execution

    Advanced Oncotherapy plc (LON:AVO) is the topic of discussion when Dr Martin Hall Analyst at Hardman & Co joins DirectorsTalk. Martin talks us through the interesting developments being made at the company, commercial deals, brings us up

    Hardman & Co

    Advanced Oncotherapy Confidence in LIGHT gaining momentum

    The Advanced Oncotherapy PLC (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has

    Hardman & Co

    Why is Advanced Oncotherapy well positioned for the future?

    Advanced Oncotherapy plc (LON:AVO) is the topic of conversation when Dr Martin Hall, Head of Life Sciences at Hardman & Co joins DirectorsTalk. Martin talks us through some interesting developments at the company, explains what has

    Hardman & Co

    Advanced Oncotherapy FLASH benefits from new US reimbursement

    Advanced Oncotherapy‘s (LON:ONC) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked